BMRN: Summary for BioMarin Pharmaceutical Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 1:08am EST - Canadian Markets open in 8 hours and 22 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

BioMarin Pharmaceutical Inc. (BMRN)

On Nov 24: 16.67 USD

0.30 (1.77%)

MORE ON BMRN

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

BioMarin Pharmaceutical Inc. (NasdaqNM:BMRN) Delayed quote data

After Hours: 16.67 0.00 (0.00%) as of 4:59pm EST on 11/24/09

Last Trade:	16.67 USD
Trade Time:	Nov 24
Change:	0.30 (1.77%)
Prev Close:	16.97
Open:	16.89
Bid:	16.16 x 100
Ask:	17.11 x 100
1y Target Est:	20.69

Day's Range:	16.60 - 17.08
52wk Range:	9.93 - 21.23
Volume:	1,034,352
Avg Vol (3m):	1,410,940
Market Cap:	1.68B
P/E (ttm):	89.62
EPS (ttm):	0.19
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add BMRN to Portfolio

Download Data

HEADLINES

•	BioMarin to Present at the NASDAQ OMX 23rd Investor Program
	PRNewswire (Tue 4:00pm)

•	Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
	PRNewswire (Fri, Nov 13)

•	Healthcare Bill Will Be Law By New Year Says Morningstar Strategist
	Wall Street Transcript (Mon, Nov 9)

•	United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
	PRNewswire (Thu, Nov 5)

•	BioMarin to Present at the Credit Suisse Healthcare Conference
	PRNewswire (Wed, Nov 4)

•	BIOMARIN PHARMACEUTICAL INC Financials
	EDGAR Online Financials (Tue, Nov 3)

•	Finally Convinced? Benlysta Works!
	at Motley Fool (Mon, Nov 2)

•	Earnings? Yawn. Trial Data? Moving!
	at Motley Fool (Fri, Oct 30)

•	This Week's 5 Smartest Stock Moves
	at Motley Fool (Fri, Oct 30)

•	BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Thu, Oct 29)

More Headlines for BMRN...

ANALYST

EPS Est (next year) (Dec-09) :	-0.05
EPS Est (in 2 years) (Dec-10) :	0.23
Avg Rec (current)*:	1.9
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates.

Full Company Profile

Add to Portfolio

Email to a Friend

•